Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

BioGaia subsidiary Infant Bacterial Therapeutics gets Orphan Drug Designation in Europe

Infant Bacterial Therapeutics (IBT), subsidiary of BioGaia, is in the early stages of developing a drug to prevent necrotizing enterocolitis (NEC) which is a rare and fatal disease that affects premature infants. IBT has now obtained the Orphan Drug Designation for the prevention of NEC in Europe, which complements the corresponding designation in the US from FDA, granted in August 2013.Orphan drugs are either drugs or biologics intended for the treatment, diagnosis or prevention of rare diseases which are defined as life-threatening or chronically debilitating conditions affecting less

Nurminen Logistics starts co-determination negotiations on the restructuring of the Group Communication function

Nurminen Logistics Plc Stock Exchange Release 23 February 2015 at 10:00 a.m. Nurminen Logistics is planning to implement cost savings by restructuring the Group Communication function. The planned cost savings aim to improve the cost structure of the Group Administration. Nurminen Logistics Plc Olli PohjanvirtaPresident and CEOFor more information, please contact: Olli Pohjanvirta, President and CEO, tel. +358 10 545 2431. DISTRIBUTION                                                                          NASDAQ OMX HelsinkiMajor media

Welcome to Swedbank’s Annual General Meeting 2015

The shareholders in Swedbank AB are hereby given notice to the Annual General Meeting at Dansens Hus, Barnhusgatan 14, 111 24 Stockholm, on Thursday 26 March, 2015 at 10:00 am (CET).Shareholders are welcome from 08:30 am (CET). Before the Meeting it will be possible for shareholders to ask questions to the management of Swedbank. Light refreshments will also be served before the Meeting. As a service to non-Swedish speaking shareholders, the Meeting will be simultaneously interpreted into English. Notification etcShareholders who wish to attend the Meeting must be recorded in the

New products from bark to replace fossil compounds: adhesives and insulating foams from softwood bark tannins

In collaboration with its partners, VTT developed tannin extraction from softwood bark as part of an ERA-NET project. At least 130 kg of crude tannin powder can be produced from one tonne of dry wood bark, still leaving 87% of the original bark mass available for incineration. In Finland, tannin could replace, in particular, fossil-based phenols in adhesives used in the wood products industry. Hundreds of tonnes of tannin is produced from wood materials and wood bark for the needs of leather, beverage and animal feed industry in South America and South Africa in particular. However, the

Citi Mobile Challenge Launches in Jerusalem, London, Nairobi, and Warsaw

Digital Acceleration Program Fuels FinTech Innovation through CompetitionNEW YORK / LONDON – Citi today announced the launch of Citi Mobile Challenge in Europe, the Middle East and Africa, the latest part of Citi’s global Digital Acceleration effort to foster innovation within the banking industry. The virtual competition invites developers from around the world to build innovative solutions based on Citi’s digital platform. Citi’s vast global network gives developers an opportunity to have their ideas put in place in markets all over the worldRegistration for the Challenge will begin on

KONE acquires German elevator company Janzhoff Aufzüge GmbH

KONE Corporation, press release, February 23, 2015 KONE Corporation, a global leader in the elevator and escalator industry, has acquired Janzhoff Aufzüge GmbH, a German company providing elevators as well as maintenance and modernization services. Founded in 1945, Janzhoff Aufzüge is based in Dortmund and was previously owned by the Kapp family. The company currently has 2400 elevators in service and employs approximately 100 people. "We are happy to welcome Janzhoff Aufzüge and its skilled employees to our organization," says Axel Berkling, Managing Director, KONE Germany. "With

BIOHIT ColonView is the best colorectal cancer screening test on the market

Biohit Oyj Press Release February 20, 2015 at 10:00 a.m. local time (EET) A international study comparing colorectal cancer screening tests has been completed and the scientific report has been recently accepted for publication in an international cancer journal - Anticancer Research. A hospital-derived cohort of 300 subjects were tested using the new-generation Biohit ColonView fecal immunochemical Test (FIT) and the traditional test for fecal occult blood (FOB). The results indicate that ColonView was superior to the conventional FOB test in colorectal cancer screening due to its

NOTICE TO ANNUAL GENERAL MEETING IN HiQ INTERNATIONAL AB (PUBL)

The Board of Directors of HiQ International AB (publ) hereby gives notice to the Annual General Meeting (“AGM”), in accordance with the attached Notice. The AGM will take place on Tuesday 24 March 2015 at 10.00 a.m. at the company’s 9th floor office at Regeringsgatan 20 in Stockholm.At the general meeting inter alia the following proposals will be presented: · The Board of Directors proposes that a share split 2:1 combined with a compulsory redemption procedure shall be carried out. The procedure will imply that each share will split into one ordinary share and one redemption share.

Change of ownership in Hansa Medical

Farstorps Gård AB, previously the largest shareholder in Hansa Medical AB, has sold 3,947,368 shares in Hansa Medical, representing approx. 15 per cent. of the total number of shares and votes outstanding in the company to a selected number of Swedish and international institutional investors, including specialist healthcare funds Rhenman & Partners, Hjärt-Lungfonden and others.Important informationThe information in this press release is not directed at persons located in Australia, Canada, Hong Kong, Japan, New Zealand, the Republic of Korea, Singapore, South Africa, Switzerland, the

Hansa Medical announces fully underwritten SEK 246 million rights issue

The Board of Hansa Medical has decided on a rights issue which will provide the company with SEK 246 million before deduction of costs. The rights issue is fully guaranteed by subscription undertakings and underwriting.Important informationThe information in this press release is not directed at persons located in Australia, Canada, Hong Kong, Japan, New Zealand, the Republic of Korea, Singapore, South Africa, Switzerland, the United States or any other country where the offer or sale of subscription rights, interim shares or new shares is not permitted. The information may not be

Year End Report 2014

January 2014 - December 2014 · Rental income of SEK 608.7 million (-) · Net operating income of SEK 257.6 million (0.4) · Earnings from management operations of SEK 42.4 million (-2.7) · Changes in the value of investment properties amounted to SEK 278.4 million (-) · Changes in the value of derivative instruments affected earnings by SEK -14.2 million (-) · Profit after tax amounted to SEK 233,1 million (-2.7) · Earnings per share of SEK 3.3, before dilution · Earnings per share of SEK 2.6, after dilution Significant events during the fourth quarter · On

Orkla ASA :New 7-years Norwegian bond issue (2015-2022) and buy-back in ORK 09 (ISIN NO 001 036491.2, 2007-2017)

Based on an offer from DNB Markets regarding a swap of bonds, Orkla ASA has today completed a bond issue in the Norwegian market. A total of NOK 1,500 million has been issued, of which NOK 508 million was sold in the market and NOK 992 has been kept on Orkla ASA's own account. The bonds are issued with 7 years tenor and floating interest rate equal to 3 months NIBOR + 0.69 %-points. Simultaneously, Orkla has made a buy-back of NOK 507 mill. in ORK 09. The outstanding amount in the market is after this NOK 793 mill. After the buy-back Orkla ASA holds NOK 507 mill. on its own account.

Bridge Alliance and Ericsson partner to fuel the Internet of Things

· Bridge Alliance and Ericsson allow device manufacturers, enterprises or service providers to deploy their Internet of Things (IoT) services in multiple countries with the benefits of a domestic quality of service and commercial conditions · Ericsson deploys the Device Connection Platform as a single platform to manage IoT across the Bridge Alliance's mobile operators, covering 36 countries · Solution significantly reduces barriers to deployment for enterprises, keeping total cost of ownership low while maximizing quality of service Bridge Alliance, composed of 36 mobile

Vizrt signs USD 920k virtual studio deal with Thai broadcaster

Bergen, Norway, February 23, 2015, Vizrt Ltd. (Oslo Main List: VIZ). Vizrt Ltd. announced today a deal worth USD 920,000 for the implementation of Viz Virtual Studio products with BEC Multimedia (Channel 3) in Thailand. The broadcaster will use Viz Virtual Studio to produce news shows. Being a long-time customer of Vizrt, Viz Virtual Studio is an addition to a wide range of Vizrt products and solutions used by this major broadcaster. Vizrt was chosen due to a successful long-time relationship, a trust in Vizrt´s products and the reliable after-sales support. “We are very pleased

Update on completion of merger agreement with Nordic Capital

Bergen, Norway, February 23, 2015, Vizrt Ltd. (Oslo Main List: VIZ). Reference is made to the announcement of 10 November 2014 regarding the entry into by Vizrt Ltd. (“Vizrt” or the "Company") of a merger agreement (the "Merger Agreement") with 24 October Holding AG, an entity indirectly controlled by Nordic Capital Fund VIII[1] , and NOR Merger Sub Ltd. (which is a wholly-owned subsidiary of 24 October Holding AG), pursuant to which Nordic Capital Fund VIII will pay a cash consideration of NOK 37 (less withholding tax, if applicable) per Vizrt share for 100% of the issued

Archer Limited : Fourth Quarter and Preliminary 2014 Results

Hamilton, Bermuda (February 23, 2015) Fourth Quarter 2014 highlights · Fourth quarter revenue from continuing operations of $603.7 million · Fourth quarter EBITDA from continuing operations at $69.3 million. · Fourth quarter impairment charge of $58.9 million. · Net loss for the quarter of $90.2 million. · Fourth quarter operational cash flow of $30.9 million. · Net interest-bearing debt of $782.5 million at December 31, 2014. In connection with the earnings release, a conference call will be held at 7:00 Houston time, 13:00 London time, 14:00 Oslo time

200 000 tickets sold

In the midst of the Ladies’ sprint relay event, Falun2015 surpassed a dream threshold. 200 000 tickets have now been sold.”The demand for tickets has exceeded our expectations”, says Sven von Holst, CEO for Falun2015.The atmosphere among all the spectators is fantastic. During the first five competition days more than 100 000 visitors have come to the Lugnet arena to watch the athletes. “Early on, in the planning of this event, we set ourselves a goal to sell 170 00 tickets. That we have already sold 30 000 more than this, goes beyond all our expectations. It feels like we have crossed

Dasgupta receives American Chemical Society’s J. Calvin Giddings Award

National education awardARLINGTON, Texas -- Purnendu “Sandy” Dasgupta, the Jenkins Garrett Professor of Chemistry at The University of Texas at Arlington, has received the 2015 American Chemical Society Division of Analytical Chemistry J. Calvin Giddings Award for Excellence in Education.  The national award recognizes a scientist who has enhanced the professional development of analytical chemistry students, developed and published innovative experiments, designed and improved equipment or teaching labs and published influential textbooks or significant articles on teaching analytical

DYMISTA® approved in children 6 to 11 years of age with seasonal allergic rhinitis

Meda announces the approval by FDA (U.S. Food and Drug Administration) of Dymista, a single formulation azelastine hydrochloride and fluticasone propionate nasal spray for the relief of symptoms of seasonal allergic rhinitis in patients 6-11 years of age who require treatment with both components. Dymista was previously indicated only for adults and children 12 and older. The approved dosing for Dymista in children 6 to 11 is 1 spray/nostril BID (same as the dosing for adolescents and adults with SAR). The efficacy and safety of Dymista was demonstrated in 2 pediatric trials where

The Ultimate Day is here - exclusively at Ragdale Hall

What a difference a day makes… especially when it’s Ragdale Hall’s new Ultimate Day spa package.The Ultimate Day includes treatments unique to Ragdale Hall, specially created by our highly experienced senior beauty team and designed to ensure our guests leave relaxed and revived, from head to toe. We believe this is our finest day spa package yet, offering a unique combination of treatments, hospitality and full use of our award-winning facilities. Ultimate Day guests enjoy a 55-minute Miracle Facial, combining a Clarisonic brush cleanse, gold and natural plant collagen eye

Ossur Hf : Insider trading

Announcement Össur hf. No. 06/2015Auðkenni útgefanda/Trade ticker: OSSR Nafn útgefanda/Issuer: Össur hf. Dagsetning tilkynningar/Date of announcement: 20 February 2015 Nafn fruminnherja/Name primary insider: Jón Sigurðsson Tengsl fruminnherja við útgefanda/Insider's relation with the issuer: President & CEO Dagsetning viðskipta/Date of transaction: 20 February 2015 Tímasetning viðskipta/Time of transaction: - Tegund fjármálagernings/Type of financial instrument: Equities Kaup eða sala/Buy or Sell: Buy Fjöldi hluta/Number of shares: 80,972 Verð pr. Hlut/

Year End Report 2014

· Pandox’ operating cash flow, excluding non-recurring items, amounted to SEK 887.8 M (814.7), which corresponds to a 9 per cent increase. The increase is mainly explained by an improved global economy, increased capacity when renovated hotels have been reactivated, improved results from hotels under own operations and lower financing costs. · Property management revenues amounted to SEK 1,788.8 M (1,812.5). For comparable entities, including an adjustment for currency effects, the property management revenues increased by 5.1 percent. · Revenues from Pandox' own operations were SEK 1,

ABG Sundal Collier and HDR Partners advisors as NeuroVive completes a directed share issue of SEK 65 million

NeuroVive Pharmaceutical AB (publ) (”NeuroVive” or the “Company”, OMX:NVP) today announces that the Company has completed a directed share issue of 1.3 million new shares, which brings SEK 65 million to the Company before transaction costs.The new share issue, which was approved by the board of the Company on 19 February 2015 with authorization from the Annual General Meeting on 9 May 2014, includes 1,300,000 new shares and has been directed to a limited group of Swedish and international institutional qualified investors at a price of SEK 50 per share through a private placement procedure.

There are no items matching the current filter
There are no more items matching the current filter
Back to top